Parkinson's Disease - The Future 2012

What’s in the pipeline?

Although it is the gold standard for Parkinson’s Disease, levodopa is not the perfect treatment because of associated complications such as the development of dyskinesias and “wearing-off”. Further, it does not address other unmet needs in PD such as the ability to treat non-dopamine features and slow the clinical progression of the disease. In this new program, Dr. Warren Olanow and other experts discuss new therapies designed to address these unmet needs, both pharmacologically and with physical interventions.

Begin Program

Earn up to 4 Free CME credits

Each part of this program is worth 2.0 Hours of AMA PRA Category 1 Credit.

  • Faculty

    C. Warren Olanow, MD, FRCPC, Moderator
    Consultant/Stock Options: Ceregene, Inc.
    Stock: Clintrex
    Consultant:Novartis/Orion; Abbott/Solvay Pharmaceuticals, Inc.; Teva Neuroscience/Lundbeck; and Ipsen

    Matthew B. Stern, MD, Panelist
    Consultant: Adamas Pharmaceuticals, Inc; Civitas; Ipsen, Medtronic; Merz; NuPathe, Inc., Teva Neuroscience. Speaker: Teva Neuroscience

    Karl Kieburtz, MD, MPH Panelist
    Grants/Research Support: Medivation, Michael J Fox Foundation, Neurosearch, NIH, and Pfizer. Consultant: Abbott, Acorda, Aptiv, Biogen Idec, Biotie, Biovail, Boehringer Ingelheim, Ceregene, Civitas, Clintrex, Cynapsus, EMD Merck Serono, Genzyme, Impax, Intec, Ipsen, Isis, Knopp, Lily, Link Medicine, Lundbeck, LZ Therapeutics, Merz , Novartis, Orion, Otsuka, Pharm2B, Phytopharm, Schering-Plough, Siena Biotech, Synosia, Solvay, Synagile, Teva, UCB Pharma, Vaccinex, Vectura, Xenoport; US FDA, US VA, NIH. Legal Consultant: Pfizer, Thompson Hine, Welding Rod Litigation Defendants

    Jeffrey H. Kordower, PhD, Panelist
    Scientific Advisory Board: Ceregene, Inc., Brainstorm, Inc.
    Consultant: Kinetics Foundation

    Andres M. Lozano, MD, PhD, FRCSC, FRSC, Panelist
    Consultant: Boston Scientific, Ceregene, Eli Lily, Medtronic, St. Jude
    Editorial Board: Brain Stimulation.
    Patents, Royalties, Stock/Stock Options, Board Membership:
    Functional Neuroscience Inc.